drugset / Trial / NCT00003832

Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00003832

Phase 2 Completed 75 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer. Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment

Timeline

Start
1999-07
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject bromodeoxyuridine Unknown Intravenous

Indications